English reimbursement system for medical devices and IVD tests 

This online on-demand 70-minute seminar gives a comprehensive understanding of the hospital reimbursement landscape for medical devices in England. Additional modules cover reimbursement of IVD tests and screening methods

Available as pre-recorded webinar or full presentation in Acrobat PDF

Request a quote

England is one the most attractive markets for medical devices in Europe.

Large population, well-structured reimbursement processes and first-class research and treatment facilities make it the country of choice for market entry for medical device companies.

On the other side, market access in England is very much evidence-driven, which requires good level of clinical evidence for acceptance of novel technologies. Also, a complex reimbursement system (National Tariff Payment System) and funding framework (including commissioning by NHS England or Clinical Commissioning Groups) with a strong advisory role of National Institute for Health and Care Excellence (NICE) makes the market access environment difficult to understand and navigate in.

We built this seminar based on experience from dozens of market access projects in England, to help develop better understanding of the market access landscape in England and to inform better business decisions whether to go to this market or not and if yes, how to approach it.

What topics are reviewed?

Key stakeholders and their role in reimbursement processes

Key stakeholders are reviewed including payers, policy-makers, advising organizations, managers of procedural (OPCS) classification and payment system (HRG, National Tariff)

Specifics of commissioning processes by NHS England and Clinical Commissioning Groups (CCGs) are reviewed as well

Money flow, hospital payment system and specifics of HRG

Money flow and distribution of funds, overview of the payment models (within and outside National Tariff Payment System), composition of National Tariff, specifics of Healthcare Resource Groups (HRGs), process to introduce changes into HRG system

Innovation funding landscape

Landscape after Accelerated Access Review, Accelerated Access Collaborative, transformative technologies, Innovation and Technology Payment, Commissioning through Evaluation

Role of health technology assessment

Overview of five med tech and IVD programs at NICE, role of HTA in market access for medical devices and IVD tests

Additional modules

Reimbursement system for in-vitro diagnostic tests

A separate comprehensive overview of the reimbursement system for IVD tests in England

Organization and financing of screening methods

A separate comprehensive overview of the organizational and financing framework of screening methods (e.g. breast and cervical cancer screening) in England

What topics are not covered?

Some topics are not specifically covered in this seminar: reimbursement model in out-patient settings, reimbursement for medical aids (devices for home use), nuances of health technology assessments at NICE, funding of capital equipment

Introductory presentation also does not include details of reimbursement application processes (e.g. application form, requirements, details of the process for creation of procedure code, HRG change, adding device to the High Cost Device List etc.)

Topics that are not covered in this seminar, will be covered in the future courses. You can subscribe to our newsletter and inform us about your particular interests at the main page of the Market Access Academy

How is the seminar delivered?

Option #1: Pre-recorded webinar

One option is to watch the seminar, which is provided as a pre-recorded webinar. The duration of the webinar is 1 hour 14 minutes. Seminar is available for 6 months

Option #2: Presentation in Acrobat PDF

You can also access just the educational material - the full presentation of the seminar in Acrobat PDF

View extract from the seminar

This 3-minute extract presents overview of the reimbursement via High Cost Device List in England


Updates of the seminar

June 2019: v1 released

May 2020: Multiple changes were implemented (v2.1):

  • New stakeholder was added – NHSX
  • New slide about Device Working Groups and centralized procurement of the High Cost Device List products

April 2020: Substantial changes were implemented (v2):

  • Number of CCGs changed to 135 as of April 2020
  • Responsibility for collection of Reference Cost data was changed to NHS Digital
  • Update of the conceptual scheme of innovative landscape in England
  • New slide about the summary of available specific means to support innovative technologies in the NHS
  • Update of information about completed projects as part of the Commissioning through Evaluation program
  • Update of the information about Innovation and Technology Payment
  • New slides about Rapid Uptake Products and Pathway Transformation Fund
  • New slide about MedTech Funding Mandate

Request a quote

Click the button below to request a quote for the seminar

Do you have any remaining questions?

Check if they are answered at the main page or contact us
Check the main page

50% Complete

Two Step

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.